New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
08:52 EDTPTCTPTC Therapeutics price target raised to $43 from $34 at Roth Capital
Roth Capital increased its price target on PTC as the firm thinks that, based on recent favorable developments, the company's spinal muscular atrophy program is gaining steam. Roth believes that the compounds identified by PTC can be expanded to other neuro-muscular disorders. Roth reiterates a Buy rating on the stock.
News For PTCT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
11:37 EDTPTCTPTC Therapeutics CEO no longer owns company shares, TheStreet says
PTC Therapeutics CEO Stu Peltz sold the remaining 47,200 shares he owned in the company, TheStreet's Adam Feuerstein reports, citing a regulatory filing yesterday. The sale follows a stock rise in part fueled by takeover speculation, Feuerstein adds. Reference Link
March 19, 2015
08:11 EDTPTCTPTC Therapeutics and University of Pennsylvania partner for disease research
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use